🔍 Breakthroughs in Obesity Treatment You Need to Know!
In this week’s episode of Obesity Updates, we dive into the latest advancements shaping the future of obesity treatment.
🔹 Expanding Access – Eli Lilly offers new Zepbound dose options and savings programs, Liviniti’s LivLite solution balances cost control and access for employers
🔹 Growing US support for GLP-1 coverage – Strong bipartisan support under Medicare and Medicaid
🔹 Generic Launch – Biocon launches Liraglutide in the UK
🔹 Players to Watch – AbbVie’s partners with Gubra to develop an amylin analog for appetite suppression, Sun Pharma aims to launch obesity drug in five years
🔹 Trial Updates – Kallyope’s latest trial results, Metsera’s MET-097i demostrates significant potential
🔹 Legal News – Novo Nordisk faces investor lawsuit over CagriSema.
📢 Stay Ahead in Obesity Research!
✅ Like, share, and subscribe for weekly updates on obesity breakthroughs.
#ObesityResearch #GLP1Updates #HealthcareInnovation #PharmaNews #ObesityTreatment #ClinicalTrials #LucidQuest